Tag: Pimavanserin

Latest News

ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting

SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in...

FDA Reaffirms Safety of Pimavanserin in PD Psychosis

The agency’s postmarket review finds no new or unexpected safety risks associated with the antipsychotic, but some prescribing patterns are ‘potentially concerning.’ News Alerts Source...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy